We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Immunobiomarkers in Chronic Rhinosinusitis Correlate with Clinical Severity

By LabMedica International staff writers
Posted on 06 Jul 2022
Print article
Image: The UNI-CAP immunoanalyzer is intended for allergy testing using ImmunoCAP (Photo courtesy of Thermo Fisher Scientific)
Image: The UNI-CAP immunoanalyzer is intended for allergy testing using ImmunoCAP (Photo courtesy of Thermo Fisher Scientific)

Chronic rhinosinusitis comprises a heterogeneous group of inflammatory disorders. It is assumed that the disease process lasts over 12 weeks and is accompanied by two or more symptoms, such as nasal discharge/postnasal drip, nasal congestion, sinus pain/pressure, and anosmia/hyposmia.

Chronic rhinosinusitis (CRS) is characterized by epithelial inflammation and tissue eosinophilic infiltration. Interleukin-5 (IL-5), periostin (POSTN), and IL-33 are important factors that act as chemoattractants for eosinophils, and a tissue-remodeling protein positively correlated with eosinophils in blood and mediators of eosinophilic infiltration.

Clinical Scientists at the Medical University of Lodz (Lodz, Poland) carried out carried out a study in a cohort of 93 Caucasian patients, aged between 22 and 65 years: group I eosinophilic CRS without nasal polyps (CRSsNP) included 53 patients, 13 of whom were diagnosed with allergy; group II eosinophilic CRS with nasal polyps (CRSwNP) included 40 patients, 16 of whom were diagnosed with allergy. In each case, allergy was confirmed by skin prick testing. The reference group was composed of 40 patients with nasal septum deviation (NSD).

Tissue samples were collected during the planned endoscopic procedures. These comprised sinonasal mucosal and polyp tissue from CRS patients, or a fragment of the mucosa of the lower nasal concha from NSD patients. Blood samples were used to evaluate serum IL-5, periostin and IL-33 levels using ELISAs (Thermo Fisher Scientific, Waltham, MA, USA). Tissue samples, after processing, were examined with an Olympus light microscope (Olympus, Tokyo, Japan). The epithelial infiltration with eosinophils were evaluated. Determinations of total IgE levels were performed by an immunoenzymatic method on a UNI-CAP immunoanalyzer (Phadia, Uppsala, Sweden). The expression of IL-5, POSTN and IL-33 mRNA was determined in sinonasal mucosal samples and in nasal polyp tissue by real-time PCR.

The investigators reported that comparison between non-allergic and allergic patients with and without NP show significant differences for total IgE serum levels. NP tissue demonstrated significantly higher IL-5 and POSTN mRNA expression than the sinonasal tissue in the CRSsNP and CRSwNP groups. CRS groups demonstrated elevated IL-33 mRNA expression in comparison to controls irrespective of the presence of NP. No correlation was found between IL-5, POSTN and IL-33 mRNA expression and disease severity. CRSwNP group demonstrated significantly higher serum IL-5, POSTN and IL-33 protein levels than controls, and this corresponds to disease severity.

The authors concluded that serum IL-5, POSTN and IL-33 levels may be useful for identifying CRSwNP patients and predicting the disease severity. Clinical phenotyping of patients with CRS based on selected inflammatory markers could enhance the early recognition of sinus disease, thus representing a promising new therapeutic approach. The study was published on June 25, 2022 in the journal BMC Immunology.

Related Links:
Medical University of Lodz 
Thermo Fisher Scientific
Olympus 
Pharmacia 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
cTnI/CK-MB/Myo Test
Finecare cTnI/CK-MB/Myo Rapid Quantitative Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.